Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2-positive early breast cancer: A meta-regression analysis.
Ming-Han YangChiun-Sheng HuangDwan-Ying ChangFu-Chang HuShu-Min HuangPo-Hsiang HuangI-Chun ChenTom Wei-Wu ChenChing-Hung LinYen-Shen LuPublished in: Cancer medicine (2024)
The combination of trastuzumab and a low dose of epirubicin positively impacted the pCR rate without a significant increase in cardiotoxicity. We recommend exploring concurrent regimens for HR-negative, HER2-positive tumors to enhance pCR rates, with caution advised for HR-positive tumors due to potential cardiotoxicity.